Clinical trials: Prostate Disease
Prostate Cancer
Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this first-in-man study is to evaluate safety, tolerability and pharmacokinetics of ODM-204 in patients with metastatic castration-resistant prostate cancer.
- Trial name
- DUALIDES (NCT02344017)
- Testing
- ODM-204, Prednisone
- Where
- 4 sites in Finland, France and 2 more
- Volunteers
- 23 people
- Sponsor
- Orion Corporation, Orion Pharma
Prostatic Neoplasms
Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer
This study is designed to determine if experimental treatment with QLH12016 in combination with novel hormonal agent (NHA) is safe, tolerable, and has anti-cancer activity in patients with advanced prostate cancer.
- Trial name
- NCT07104110
- Testing
- QLH12016, abiraterone acetate, enzalutamide
- Volunteers
- 50 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Prostatic Neoplasms
Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]
Primary objectives: To determine the response rate, measurable and non measurable, to Taxotere® in the second line setting. Secondary objectives: To evaluate the overall safety and toxicity of Taxotere®/prednisone combination as…
- Trial name
- NCT00268710
- Testing
- docetaxel
- Sponsor
- Sanofi
Metastatic Prostate Cancer, Prostate Adenocarcinoma
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men…
- Trial name
- CONTACT-02 (NCT04446117)
- Testing
- Cabozantinib, Atezolizumab, Abiraterone Acetate
- Where
- 280 sites in United States, Argentina and 25 more
- Volunteers
- 575 people
- Sponsor
- Exelixis
Prostate Cancer
BR55 in Prostate Cancer: an Exploratory Clinical Trial
The purpose of this study is to determine whether BR55 is able to identify areas of VEGFR2 expression in human prostate by ultrasound molecular imaging.
- Trial name
- NCT01253213
- Testing
- BR55
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Bracco Diagnostics, Inc
Prostate Cancer
A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer
This is a prospective, multicenter, open-label, non-randomized study evaluating the ability of [89]Zr-Df-IAb2M to detect local, regional and metastatic prostate cancer confirmed by pathology.
- Trial name
- NCT02424513
- Testing
- [89Zr]Df-IAB2M
- Where
- United States
- Sponsor
- ImaginAb, Inc.
Prostate Cancer, Hormone-Dependent Prostate Cancer
A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
The aim of this study is to compare the safety and efficacy of SHR3680 with bicalutamide in the treatment of patients with hormone sensitive prostate cancer.
- Trial name
- NCT03520478
- Testing
- SHR3680, Bicalutamide
- Where
- 67 sites in Bulgaria, China and 2 more
- Volunteers
- 654 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
A Study of Pertuzumab in Participants With Prostate Cancer
This study will evaluate the efficacy and safety of intravenous (IV) pertuzumab in participants with hormone-refractory prostate cancer who have had no previous chemotherapy.
- Trial name
- NCT02480010
- Testing
- Pertuzumab
- Where
- 11 sites in France, Germany and 4 more
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients with prostate cancer. This multicenter study is planned to be conducted in patients with biochemical recurrence (BCR) of elevated PSA…
- Conditions
- Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma
- Trial name
- NCT05847348
- Testing
- 68Ga-PSMA-11, PET/CT or PET/MRI
- Where
- 8 sites in China
- Volunteers
- 110 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer
Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results.
- Trial name
- NCT01071915
- Testing
- Degarelix 240/80 mg
- Where
- 11 sites in South Korea
- Volunteers
- 157 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621.
- Trial name
- ACTIVATED-4-PC (NCT07192614)
- Testing
- AZD6621
- Where
- 26 sites in United States, Belgium and 7 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms, Prostate Cancer
Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer
This trial uses a ultra high-resolution ultrasound system and specialized transducer, intended for use in prostate imaging. The system's image resolution is significantly better than the standard of care, due to its higher…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Cancer of the Prostate
- Trial name
- NCT02079025
- Testing
- High-resolution ultrasound guided prostate biopsy, Standard ultrasound guided prostate biopsy
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,676 people
- Sponsor
- Exact Imaging
Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)
Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)
This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy of ozarelix compared to placebo in the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia…
- Trial name
- NCT00743184
- Testing
- ozarelix
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Prostate Cancer, Prostate Cancer Metastatic Disease
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer
The aim of this study is to assess the safety and dosimetry of [68Ga]Ga-OncoACP3 in patients with prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic Disease, PSA Level Greater Than 0.2
- Trial name
- OncoACP-3 (NCT06840535)
- Testing
- [68Ga]Ga-OncoACP3
- Where
- 3 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Philogen S.p.A.
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
- Trial name
- NCT05413850
- Testing
- Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only)
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 82 people
- Sponsor
- Blue Earth Therapeutics Ltd
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Benign Prostatic Hyperplasia (BPH)
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Inflammation is reported as one of the most recent hypotheses to explain BPH. Recent published works pointed out that urine and serum markers could be used for detection of prostatic inflammation.
- Trial name
- PERMIN (NCT01604811)
- Testing
- Permixon® 160 mg, Tamsulosine Arrow LP
- Where
- 32 sites in France, Italy and 2 more
- Volunteers
- 206 people
- Sponsor
- Pierre Fabre Medicament
Cancer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either…
- Trial name
- NCT04485013
- Testing
- TTX-080, pembrolizumab, cetuximab
- Where
- 41 sites in United States
- Volunteers
- 240 people
- Sponsor
- Tizona Therapeutics, Inc
Prostate Cancer
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301EXT is an open-label, nonrandomized, phase 1 extension study of PSMA ADC administered IV in subjects with progressive CMPC that has progressed after prior…
- Trial name
- NCT01414296
- Testing
- PSMA ADC
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Metastatic Cancer, Neoplasm, Prostate
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC.
- Conditions
- Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer
- Trial name
- NCT05422911
- Testing
- Abiraterone acetate, Apalutamide, Enzalutamide
- Where
- 12 sites in United States
- Volunteers
- 192 people
- Sponsor
- Sun Pharmaceutical Industries Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.